CD79A and esophageal squamous cell carcinoma: D The 3-year OS rates in ESCC patients with IgA < 56.56 EU (n = 62) and IgA > 56.56 EU (n = 16) were 41.45% and 0, respectively, in late clinical stage (P = 0.48).